MedBiquitous Annual Conference Includes Presentation about ER/LA Opioid Analgesics REMS

April 25, 2013
Posted by: 
Tamar Hosansky

Presentation about CE's role in ER/LA Opioid Analgesics REMS

The MedBiquitous Annual Conference 2013, held in April in Baltimore, included a panel presentation about the role of continuing education in the US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics. Kate Regnier, MA, MBA, ACCME Deputy Chief Executive and COO, explained how continuing education accreditors will support data collection and reporting about REMS-compliant CE activities, as mandated by the FDA. The Medical Education Metrics Standard (MEMS) 2.0, created by MedBiquitous, offers a system for collecting data about REMS-compliant CE across the health professions. The ACCME is adapting its Program and Activity Reporting System (PARS) to facilitate this data collection for CME providers that are developing REMS-compliant CE activities. Ms. Regnier also described the scope of the ACCME accreditation system and explained how the accreditation requirements safeguard the independence of ER/LA Opioid Analgesic REMS-compliant CE activities.

For more information about the ER/LA Opioid Analgesic REMS and the issue of opioid abuse, please see the following resources:

FDA Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids: This FDA information page includes links to the ER/LA Opioid Analgesic REMS blueprint, Q&A, news release, and other resources.

ER/LA Opioid Analgesics REMS: This REMS Program Companies Web site includes information for CE providers.

ACCME Audio Commentary: Murray Kopelow, MD, ACCME President and CEO, discusses the role of accredited CME and the ACCME in supporting the ER/LA Opioid Analgesic REMS.

Ask ACCME Q&A about the ER/LA Opioid Analgesic REMS.

Johns Hopkins MedBiquitous Project Supports FDA REMS Initiative Addressing ER/LA Opioid Abuse: This news release explains how MEMS 2.0, created by the MedBiquitous Consortium, will permit data about REMS-compliant CE programs from across the health professions to be successfully aggregated into a single data set describing the entire nation’s accredited CE efforts in support of the FDA’s REMS initiative.

Office of National Drug Control Policy: This White House Web site features information and resources about prescription drug abuse and a link to the 2011 Prescription Drug Abuse Prevention Plan. The plan includes the role of continuing health care education in addressing the national prescription drug problem.

Joint Commission Issues New Sentinel Event Alert: Safe Use of Opioids in Hospitals: The recommendations include education and training for clinicians and staff who care for patients, identifying gaps, and developing improvement strategies.